Part 5: Acute coronary syndromes

International Liaison Committee on Resuscitation

The American Heart Association and the American College of Cardiology,1,2 the European Society of Cardiology3,4 and others5 have developed comprehensive guidelines for the in-hospital management of patients with ST-elevation myocardial infarction (STEMI)2 and for unstable angina (UA) and non-ST-elevation MI (NSTEMI).1 The International Liaison Committee on Resuscitation (ILCOR) Acute Coronary Syndromes (ACS)/Acute Myocardial Infarction (AMI) Task Force reviewed the evidence specifically related to diagnosis and treatment of ACS/AMI in the out-of-hospital setting and the first hours of care in the in-hospital setting, typically in the emergency department (ED).

Much of the research concerning the care of the patient with ACS has been conducted on in-hospital populations rather than in the ED or out-of-hospital settings. By definition, extending the conclusions from such research to the early ED management strategy or the out-of-hospital setting requires extrapolation classified as level of evidence 7.

Diagnostic tests in ACS and AMI

The sensitivity, specificity, and clinical impact of various diagnostic strategies in ACS/AMI have been evaluated. These include signs and symptoms, cardiac markers, and 12-lead electrocardiogram (ECG). The standard ILCOR/AHA levels of evidence (described in Part 1: “Introduction”) pertain largely to therapeutic interventions. For this reason, in the evaluation of evidence for diagnostic accuracy the reviewers used the Centre for Evidence-Based Medicine (CEBM) levels of evidence for diagnostic tests (http://www.cebm.net/levels_of_evidence.asp).

The CEBM levels are cited as “levels” and the ILCOR/AHA levels of evidence are designated with “LOE,” for “level of evidence.” Neither signs and symptoms nor cardiac markers alone are sufficiently sensitive to diagnose AMI or ischaemia in the prehospital setting or the first 4–6 h in the ED. The 12-lead ECG in the ED and out-of-hospital settings is central to the initial triage of patients with possible ACS.

Diagnostic and prognostic test characteristics of signs and symptoms of ACS/AMI

W221A, W221B

Consensus on science

Diagnosis. Four CEBM level 1B validating cohort studies6–9 and nine CEBM level 2A-4 studies10–18 do not support the use of any clinical signs and symptoms independent of ECG, cardiac biomarkers, or other diagnostic tests to rule in or rule out ACS/AMI in prehospital or ED settings. Although some signs are more sensitive and specific than others, no sign or symptom evaluated exceeded 92% sensitivity in the higher LOE studies (most reported sensitivity of 35–38%) or 91% specificity (range 28–91% in highest CEBM levels).7

Prognosis and clinical impact. In three CEBM level 1a systematic reviews,10,19,20 10 CEBM level 1b validating cohort studies6–9,21–28 and 21 CEBM level 2a-4 studies,11–13,15–18,27–40 a variety of signs and symptoms assisted in the diagnosis of ACS/AMI and had clinical impact (defined as triage and some treatment and investigational decisions) on the out-of-hospital emergency management and
risk assessment for coronary atherosclerosis and unstable syndromes.

**Treatment recommendation** Signs and symptoms of ACS/AMI may be useful in combination with other important information (biomarkers, risk factors, ECG, and other diagnostic tests) in making triage and some treatment and investigational decisions in the out-of-hospital setting and the ED. Signs and symptoms are not independently diagnostic of ACS/AMI.

**Diagnostic and prognostic test characteristics of cardiac biomarkers for ACS/AMI**

*Consensus on science*

**Diagnosis.** All literature reviewed showed that biomarkers (creatine kinase [CK], creatine kinase myocardial band [CK-MB], myoglobin, troponin I [TnI], troponin T [TnT]) were helpful in the diagnosis of ACS/AMI. But only six studies41—44 (CEBM level 1b; ILCOR/AHA LOE 7 [extrapolated from in-hospital setting]) and serial marker testing over time41—43,45—49,51,56,58,60—69 (CEBM level 1b; ILCOR/AHA LOE 7 [extrapolated from in-hospital setting]) improved test performance.

Six out-of-hospital studies70—75 (CEBM level 1b) showed consistent lack of support for the use of cardiac biomarkers in diagnosing AMI in the out-of-hospital phase (sensitivity 10—25%; specificity 92—100%).

**Prognosis.** Two systematic reviews (CEBM level 1a)76,77 and 21 additional studies78—98 (18 CEBM level 1b and 3 ILCOR/AHA LOE 7) documented consistent ability of cardiac biomarker testing to identify patients at increased risk of adverse outcome. One systematic review (CEBM level 1a)76 suggested that risk assessment cannot be based exclusively on cardiac biomarker results (30-day mortality range for patients with suspected ACS and negative troponin results: 0.7—4.4%).

**Treatment recommendation.** Emergency physicians should obtain cardiac biomarkers for all patients with suspected ACS/AMI. Serial time points (increasing interval from onset of symptoms to testing), and multimarker strategies greatly improve sensitivity for detection of myocardial ischaemia or infarction but are insensitive for ruling out these diagnoses in the out-of-hospital setting or within the first 4—6h of evaluation in the ED.

**ED Interpretation of 12-lead ECG for STEMI**

*Consensus on science*

**Diagnostic characteristics—out-of-hospital.** One meta-analysis plus five prospective nonrandomised consecutive case series of patients with chest pain (CEBM level 1b-1c)99—104 and five review articles ILCOR/AHA LOE 711,20,105—107 showed that trained out-of-hospital care providers (paramedics and nurses) could identify ST elevation accurately in the resting out-of-hospital 12-lead ECG of patients with chest pain suspected of having STEMI. The out-of-hospital care providers achieved a specificity of 91—100% and sensitivity of 71—97% compared with emergency physicians or cardiologists. Of note, left bundle branch block paced rhythm and idioventricular rhythm may affect the diagnostic test accuracy because they were excluded in some studies and not mentioned in others.

**Prognostic characteristics—ED.** ST elevation (>0.1 mV elevation in two or more adjacent limb leads or in two or more adjacent precordial leads with reciprocal depression) was the most discriminating single ECG feature for diagnosis of STEMI (likelihood ratio [LR] of 13.1; 95% confidence interval [CI], 8.28—20.6).11 Emergency physicians blinded to biomarker results established the diagnosis of STEMI using admission ECGs with a very high specificity of 99.7% (95% CI, 98—99.9%; LR+ 145; 95% CI, 20.2—1044), although sensitivity was low at 42% (95% CI, 32—52%)103,108,109 (CEBM 1b-1c; ILCOR/AHA LOE 7).11

**Treatment recommendation**

*Out-of-hospital.* Trained out-of-hospital personnel can accurately identify acute STEMI in prehospital 12-lead ECGs obtained in patients with ACS. The ECG is used in combination with chest pain symptoms, assessment of risk factors, and other diagnostic tests to rule out alternative diagnoses. Out-of-hospital interpretation of a single 12-lead ECG with stringent inclusion criteria (i.e. ST elevation >0.1 mV in two or more adjacent precordial leads or two or more adjacent limb leads and with reciprocal depression) has a high specificity for the diagnosis of STEMI.

*Emergency department.* In the ED the interpretation of a single 12-lead ECG with rigid inclusion criteria (see above) is discriminating for the diagnosis of STEMI with a relatively low sensitivity but a high specificity for this diagnosis.

**Acute therapeutic interventions**

Few studies have been published to guide out-of-hospital interventions for ACS and AMI. Extrapolat-
Part 5: Acute coronary syndromes

Adjunctive therapies

Oxygen therapy

Consensus on science. One animal study (LOE 6) showed a reduction in infarct size when supplementary oxygen was provided during left anterior descending coronary artery occlusion. One human study (LOE 5) showed improvement in ECG findings, but one double-blind, randomised human trial (LOE 2) of supplementary oxygen versus room air failed to show a long-term benefit of oxygen therapy for patients with MI.

Treatment recommendation. Supplementary oxygen should be given to patients with arterial oxygen desaturation (arterial oxygen saturation [SaO2] <90%). Given the safety profile of oxygen in this population and the potential benefit in the patient with unrecognized hypoxia, it is reasonable to give supplementary oxygen to all patients with uncomplicated STEMI during the first 6h of emergency management.

Aspirin (acetylsalicylic acid)

Consensus on science. Eight randomised controlled trials (RCTs) (LOE 1) showed decreased mortality rates when acetylsalicylic acid (ASA) (75–325mg) was given to hospitalized patients with ACS. The International Study of Infarct Survival (ISIS)-2 trial used 160mg/day orally (odds reduction =0.23; 95% CI, 0.15–0.30). Two studies (LOE 1) addressed specific ASA dose, but the standard of 160mg enteric-coated ASA has still been maintained from ISIS-2. Two studies showed that chewed (LOE 3) or soluble ASA (LOE 6) provides more rapid bioavailability than swallowed tablets. Two nonblinded studies (LOE 3) showed that 50mg of intravenous (IV) ASA was >90% effective in inhibiting thromboxane A2 and inhibits platelets effectively.

Heparins

Consensus on science

UA/NSTEMI Six in-hospital RCTs (LOE 1) and LOE 2) and additional studies (including seven meta-analyses, 135–141) documented similar or improved composite outcomes (death, MI or recurrent angina, or recurrent ischaemia or revascularisation) after giving low-molecular-weight heparin (LMWH) instead of unfractionated heparin (UFH) to patients with UA/NSTEMI within the first 24–36h after onset of symptoms. No study evaluated the early use of LMWH versus UFH in the first 6h of management.

Extrapolation (LOE 7) from one RCT133 and one meta-analysis (LOE 1) suggests that changing from one form of heparin to another (crossover of antithrombin therapy) during initial treatment of an acute event may not be safe or effective in patients with UA/NSTEMI.

There is no evidence that LMWH is superior to UFH in the group of patients who will receive early percutaneous coronary intervention (PCI).

STEMI. In two RCTs (LOE 1; LOE 2) and additional studies, including one meta-analysis (LOE 1), LMWH (specifically enoxaparin) improved overall TIMI flow145 (coronary reperfusion) and ischemic outcomes better than UFH when given to patients with STEMI within 6h of onset of symptoms. TIMI flow grade was defined by investigators from the TIMI study145 as the degree of reperfusion, ranging from 0 for no flow through 3 for complete, brisk flow.
Two studies (LOE 1\textsuperscript{146}; LOE 2\textsuperscript{147}) in the out-of-hospital setting documented improved composite outcomes with LMWH (specifically enoxaparin) in comparison with UFH, when given to patients with STEMI as adjunctive therapy to fibrinolysis. This must be balanced against the increase in intracranial haemorrhage in patients >75 years receiving LMWH (enoxaparin) that was observed in one of these RCTs (LOE 2).\textsuperscript{147}

In patients with STEMI proceeding to PCI, there is no evidence in favour of LMWH. In one RCT (LOE 1)\textsuperscript{148} there was no difference in the incidence of death, reinfarction, or recurrent angina with LMWH (enoxaparin) in comparison with UFH when given to patients who were ineligible for reperfusion therapy.

Treatment recommendation

**UA/NSTEMI.** In the ED giving LMWH instead of UFH in addition to aspirin to patients with UA/NSTEMI may be helpful. There is insufficient evidence to identify the optimal time for administration after onset of symptoms. In-hospital administration of UFH is recommended if reperfusion is planned within the first 24—36 h after onset of symptoms. There is insufficient evidence to recommend for or against treatment with LMWH in UA/NSTEMI in the out-of-hospital setting. Changing from one form of heparin to another (crossover of antithrombin therapy) during an acute event is not recommended.

**STEMI.** LMWH is an acceptable alternative to UFH as ancillary therapy for patients with STEMI who are <75 years and receiving fibrinolytic therapy. LMWH should not be given if significant renal dysfunction (serum creatinine >2.5 mg dl\textsuperscript{-1} in men or 2 mg dl\textsuperscript{-1} in women) is present. UFH is recommended for patients ≥75 years as ancillary therapy to fibrinolysis.

Heparin may be given to STEMI patients who do not receive reperfusion therapy. These include patients at high risk for cardioembolic events and those on prolonged bedrest. UFH or LMWH may be used. Patients receiving LMWH should have no significant renal dysfunction.

**Clopidogrel**

\textsuperscript{W228A}

Consensus on science. In two in-hospital, randomised, double-blind, controlled trials (LOE 1)\textsuperscript{149,150} and four post hoc analyses (LOE 7),\textsuperscript{151--154} clopidogrel was effective in reducing the combined event rate (stroke, nonfatal infarction, deaths from cardiovascular causes, refractory ischaemia, heart failure, and need for revascularisation) in patients with suspected ACS with evidence of ischaemia but no infarction. In these studies clopidogrel was given within the first 4 h of presentation to the hospital in addition to standard care (ASA, heparin) to patients with ACS who had a rise in serum level of cardiac biomarkers or new ECG changes consistent with ischaemia but no ST-segment elevation.

One large randomised, double-blind, controlled trial (LOE 7)\textsuperscript{155} documented no significant increase in risk of bleeding with clopidogrel in comparison with ASA. One large multicenter RCT (LOE 1)\textsuperscript{156} documented a significant reduction in adverse ischemic events at 28 days after elective PCI when clopidogrel was given at least 6 h before elective PCI.

One multicenter, randomised, double-blind, controlled trial (LOE 1)\textsuperscript{157} documented a significant reduction in the composite end point of an occluded infarct-related artery (defined by a TIMI flow grade of 0 or 1) on angiography or death or recurrent MI before angiography when clopidogrel (300 mg oral loading dose) was given at the time of initial management (followed by a 75-mg daily dose for up to 8 days in hospital) to patients up to 75 years with STEMI who were treated with fibrinolysis, ASA, and heparin (LMWH or UFH).

In one large prospective STEMI trial (the CURE [Clopidogrel in Unstable angina to prevent Recurrent Events] trial),\textsuperscript{152} preoperative clopidogrel was associated with a trend toward increased postoperative reoperation for bleeding in the 2072 patients who underwent coronary artery bypass graft (CABG) surgery. A second prospective trial (LOE 1)\textsuperscript{157} failed to show any increase in bleeding in the 136 patients who underwent CABG within 5—7 days of receiving clopidogrel. A subsequent risk to benefit ratio analysis concluded that the bleeding risk with clopidogrel in patients undergoing CABG was overestimated.\textsuperscript{154}

Treatment recommendation. Give a 300-mg oral loading dose of clopidogrel in addition to standard care (ASA, heparin) to patients with ACS within 4—6 h of contact if they have:

- A rise in serum cardiac biomarkers or new ECG changes consistent with ischaemia when a medical approach or PCI is planned in the absence of ST-segment elevation.
- STEMI in patients up to 75 years of age receiving fibrinolysis, ASA, and heparin.

Although in one large trial\textsuperscript{152} preoperative clopidogrel was associated with increased reoperation for postoperative bleeding, the recent CLARITY TIMI 28 trial\textsuperscript{157} did not document increased bleed-
ing in 136 patients undergoing CABG within 5–7 days of receiving clopidogrel. Current ACC/AHA recommendations advise withholding clopidogrel for 5–7 days before planned CABG.

It is reasonable to give clopidogrel 300 mg orally to patients with suspected ACS (without ECG or cardiac marker changes) who have hypersensitivity to or gastrointestinal intolerance of ASA.

Glycoprotein IIb/IIIa inhibitors

Consensus on science

UA/NSTEMI. Two studies (LOE 158; LOE 2159) and two meta-analyses (LOE 1158,160) showed a reduction in the combined end point of death or recurrent ischaemia when glycoprotein (GP) IIb/IIIa inhibitors were added to standard therapy (including ASA and heparin) for patients with high-risk UA/NSTEMI treated with PCI. High-risk features include persistent ongoing pain due to ischaemia, haemodynamic or rhythm instability due to ongoing ischaemia, acute or dynamic ECG changes, and any elevation in cardiac troponins attributed to ACS.

Two studies (LOE 158,161) and three meta-analyses (LOE 1164,165) failed to show a reduction in the combined end point of death or recurrent ischaemia in patients with UA/NSTEMI treated with tirofiban or eptifibatide without PCI. Two studies (LOE 1164,165) showed that abciximab given in addition to standard therapy but without PCI in patients with UA/NSTEMI did not reduce the combined end point of death or recurrent ischaemia.

No published studies evaluated the out-of-hospital use of GP IIb/IIIa inhibitors. Three studies (LOE 1158,160,163) showed the safety (as defined by incidence of major haemorrhagic complications) of GP IIb/IIIa inhibitors when given to ACS patients within 24–48 h of onset of symptoms.

STEMI. In multiple studies (LOE 1166–168; LOE 2169–172; LOE 4173; LOE 7174) there was no reduction in the combined end point of death or recurrent ischaemia when tirofiban or eptifibatide were given in combination with reduced-dose fibrinolytics to patients with STEMI in the absence of PCI.

Two RCTs (LOE 1165,177) in patients with STEMI treated with abciximab and fibrinolytics showed no reduction in the combined end point of death or recurrent ischaemia. One meta-analysis (LOE 1178) showed reduction in short-term reinfarction rate when abciximab was given with fibrinolytics or PCI, whereas the benefits in mortality-rate reduction were seen only in patients treated with PCI.

One RCT failed to show a benefit with tirofiban in addition to standard therapy when given out-of-hospital (LOE 2).172 Another study demonstrated the feasibility of using abciximab in the out-of-hospital setting (LOE 7).175 A third study showed a trend toward improved patency of infarct-related artery with PCI (LOE 3).179

Treatment recommendation

High-risk UA/NSTEMI. If revascularisation therapy (PCI or surgery) is planned, it is safe to give GP IIb/IIIa inhibitors in addition to standard therapy (including ASA and heparin) to patients with high-risk UA/NSTEMI in the ED. This therapy may reduce the risk of death or recurrent ischaemia. High-risk features of UA/NSTEMI are defined in the consensus on science statement above.

If revascularisation therapy is not planned, the recommendation for use of GP IIb/IIIa varies by drug. Tirofiban and eptifibatide may be used in patients with high-risk UA/NSTEMI in conjunction with ASA and LMWH if PCI is not planned. But abciximab can be harmful in patients with high-risk UA/NSTEMI if early (e.g. 24 h) PCI is not planned. STEMI. Abciximab is not currently recommended in patients receiving fibrinolytics for STEMI. In patients treated with PCI without fibrinolysis, abciximab may be helpful in reducing mortality rates and short-term reinfarction. There is no evidence documenting a better outcome by giving GP IIb/IIIa inhibitors out of hospital or early in the ED.

Reperfusion strategies

Out-of-hospital fibrinolytics for STEMI

Consensus on science. One meta-analysis (LOE 1180) and multiple studies (LOE 1181,182; LOE 2183–185; LOE 3186–188; LOE 4189–192; LOE 5193; LOE 7194–196) documented reduced time to injection of fibrinolytics when given by out-of-hospital providers (physicians, nurses, or paramedics) to patients with STEMI and no contraindications to fibrinolysis. In most studies the duration of symptoms was from 30 min to 6 h from onset of symptoms. Using the same criteria, one meta analysis (LOE 1180) and eight additional studies (LOE 1181,182; LOE 2183–185; LOE 3186–188; LOE 4189–192; LOE 5193; LOE 7194–196) documented reduced risk of mortality with out-of-hospital fibrinolysis.

Treatment recommendation. Out-of-hospital administration of fibrinolytics by paramedics, nurses, or physicians using an established protocol is safe and feasible for patients with STEMI and no
contraindications. This requires adequate provisions for the diagnosis and treatment of STEMI and its complications, including strict treatment directives, fibrinolytic checklist, ECG acquisition and interpretation, defibrillators, experience in ACLS protocols, and the ability to communicate with medical control. Physicians may give out-of-hospital fibrinolytics to patients with symptoms compatible with ACS and signs of true posterior infarctions (no ST elevation).

**Fibrinolytics in the ED management of STEMI**

- **Consensus on science.** A prospective cohort study (LOE 3)\(^{200}\) and 11 additional studies (LOE 3\(^{201}\)–\(^{208}\); LOE 4\(^{209}\); LOE 5\(^{210}\)\(^{,}\)\(^{211}\)) documented reduced delay to injection of fibrinolytics and some decrease in mortality (LOE 3\(^{200}\),\(^{212}\)) and improved left ventricular function (LOE 3\(^{206}\)) when fibrinolytics were given in the ED to selected patients with STEMI (defined in studies with variable ST-elevation criteria with or without new onset left bundle branch block (LBBB) \pm posterior infarct) and no contraindications.

- **Treatment recommendation.** In the ED patients with symptoms of ACS and ECG evidence of either STEMI (presumably) new LBBB, or true posterior infarction should be given fibrinolysis if fibrinolysis is the treatment of choice and there are no contraindications. The emergency physician should give fibrinolytics as early as possible according to a predetermined protocol.

**Primary PCI compared with ED or out-of-hospital fibrinolysis**

- **Consensus on science.** Six randomised studies (LOE 1),\(^{213}–^{218}\) three meta-analyses (LOE 1),\(^{219}–^{221}\) and 24 additional studies (LOE 2–4)\(^{222}–^{248}\) compared primary PCI with fibrinolysis in patients with STEMI. These studies documented consistent improvement in the combined end point of death, stroke, and reinfarction when PCI was undertaken by skilled personnel in a high-volume center (i.e. >75 procedures per operator annually) with minimal delay. Minimal delay was defined as balloon inflation \(\leqslant 90\) min after first medical contact (i.e. contact with a healthcare provider who can make a decision to treat or transfer). In these studies the typical additional delay from decision to treat to either PCI or ED fibrinolysis was \(\leqslant 60\) min.

One study (LOE 1)\(^{217}\) and a post hoc subgroup analysis (LOE 7)\(^{246}\) of fibrinolysis compared with PCI showed no difference in survival rates when fibrinolysis was initiated within 2 h\(^{246}\) or 3 h\(^{217}\) after onset of symptoms.

- **Treatment recommendation.** All patients presenting with STEMI within 12 h of the onset of symptoms should be evaluated for reperfusion therapy (i.e. fibrinolysis or PCI).

Primary PCI is the preferred reperfusion strategy in STEMI with symptom duration >3 h if a skilled team can perform primary PCI in \(\leqslant 90\) min after first medical contact with the patient or if there are contraindications to fibrinolysis.

If the duration of symptoms is \(\leqslant 3\) h, treatment is more time-sensitive, and the superiority of out-of-hospital fibrinolysis, immediate in-hospital fibrinolysis, or transfer for primary PCI is not established (see below for further discussion of transfer).

Early revascularisation (i.e. surgery, primary or early PCI, defined as PCI \(\leqslant 24\) h after fibrinolysis) is reasonable in patients with cardiogenic shock, especially for patients <75 years.

**Primary and secondary prevention interventions**

Traditional preventive interventions usually start with the first admission with a confirmed diagnosis of ACS. Therapeutic options include antiarrhythmics, \(\beta\)-blockers, angiotensin-converting enzyme (ACE) inhibitors, and HMG-CoA reductase inhibitors (statins). The current evidence indicates that with the exception of \(\beta\)-blockers, none plays a significant role in the out-of-hospital and ED management of ACS.

**Antiarrhythmics**

- **Lidocaine**

  - **Consensus on science.** When lidocaine was given by physicians or paramedics for primary prophylaxis within the first 4 h of a suspected STEMI in the out-of-hospital setting, four meta-analyses (LOE 1)\(^{248}–^{251}\) and two RCTs (LOE 2)\(^{250}–^{252}\) showed a trend toward increased mortality rates. In addi-
Part 5: Acute coronary syndromes

Magnesium
Consensus on science. Giving magnesium prophylactically to patients with STEMI has produced mixed results. One study (LOE 2) showed a decrease in mortality and symptomatic arrhythmias. One meta-analysis (LOE 1) and two RCTs (LOE 1) showed a decrease in mortality but no reduction in ventricular arrhythmias. One small RCT (LOE 2) showed that magnesium reduced the incidence of ventricular tachycardia, but it was underpowered to assess mortality. The definitive study on the subject is the ISIS-4 study (LOE 1). ISIS-4 enrolled >58,000 patients and showed a trend toward increased mortality when magnesium was given in-hospital for primary prophylaxis to patients within the first 4h of known or suspected AMI.

Disopyramide, mexiletine, and verapamil
Consensus on science. One multi-antiarrhythmic meta-analysis (LOE 1) and four RCTs (LOE 2) showed no effect on mortality when a variety of antiarrhythmic drugs (disopyramide, mexiletine, and verapamil) were given for primary prophylaxis by paramedics or physicians to patients within the first 4h of known or suspected AMI.

Treatment recommendation for antiarrhythmics. There is insufficient evidence to support the routine use of any antiarrhythmic drug as primary prophylaxis within the first 4h of proven or suspected AMI. This conclusion does not take into account the potential effect of β-blockers discussed below.

β-Blockers
Consensus on science. Two in-hospital RCTs (LOE 1) and two supporting studies (LOE 2) completed before the advent of fibrinolytics documented decreased mortality, reinfarction, ventricular fibrillation, supraventricular arrhythmias, and cardiac rupture in patients treated with β-blockers. In patients with AMI who received fibrinolytics, treatment with IV β-blockade within 24h of onset of symptoms reduced rates of reinfarction and cardiac rupture. IV β-blockade may reduce mortality in patients undergoing primary PCI who are not on oral β-blockers (LOE 7). β-Blocker therapy was initiated in the ED for most of these trials; only one included out-of-hospital administration.

One small trial (LOE 2) showed a trend toward decreased mortality when IV β-blockers were given for unstable angina.

Treatment recommendation. In the ED treat ACS patients promptly with IV β-blockers followed by oral β-blockers. β-Blockers are given irrespective of the need for revascularisation therapies. Contraindications to β-blockers include hypotension, bradycardia, heart block, moderate to severe congestive heart failure, and reactive airway disease.

ACE Inhibitors
Consensus on science. Seven large clinical trials (LOE 1), two meta-analyses (LOE 1), and 11 minor trials (LOE 1) documented consistent improvement in mortality when oral ACE inhibitors were given to patients with AMI with or without early reperfusion therapy. ACE inhibitors should not be given if hypotension (systolic blood pressure <100 mmHg or more than 30 mmHg below baseline) is present or a contraindication to these drugs exists.

One large, randomised, double-blind, placebo-controlled trial (LOE 1) and two small randomised trials (LOE 4) in adults documented a trend toward a higher mortality rate if an IV ACE inhibitor was started within the first 24h after onset of symptoms in the hospital setting. There is no literature evaluating the therapeutic role of ACE inhibitors in the out-of-hospital setting.

Treatment recommendation. Start an oral ACE inhibitor within 24h after onset of symptoms in patients with MI whether or not early reperfusion therapy is planned. Do not give an ACE inhibitor if the patient has hypotension (systolic blood pressure <100 mmHg or more than 30 mmHg below baseline) or if the patient has a known contraindication to these drugs. ACE inhibitors are most effective in patients with anterior infarction, pulmonary congestion, or left ventricular ejection fraction <40%.
There is no evidence to recommend for or against starting ACE inhibitors in the out-of-hospital setting. Avoid giving IV ACE inhibitors within the first 24h after onset of symptoms because they can cause significant hypotension during this phase.

**HMG CoA reductase inhibitors (statins)**

Consensus on science. Nine RCTs (LOE 7)312—320 and additional small studies (LOE 3—7)321—323 documented a consistent decrease in the incidence of major adverse cardiovascular events (reinfarction, stroke, necessary intervention for recurrent angina, and rehospitalisation) when statins were given within a few days after onset of ACS. There are few data on patients treated within 24h of the onset of symptoms.

One retrospective analysis (LOE 4)324 and data from one registry (LOE 4)325 showed that patients presenting with ACS who are already taking statins should continue to take them.

There are no data on the initiation of statin therapy out-of-hospital or in the ED for patients with ACS.

Treatment recommendation. It is safe and feasible to start statin therapy early (within 24h) in patients with ACS or AMI; once started, continue statin therapy uninterrupted.

**Healthcare system interventions for ACS/AMI**

Novel strategies have been developed and evaluated to improve the speed and quality of care delivered to patients with ACS. Many strategies have been shown to be safe, effective, and feasible in the prehospital setting and ED. Such strategies include out-of-hospital 12-lead ECG and advance ED notification, interfacility transfer of the patient for PCI, and a combined strategy of interfacility transfer after fibrinolysis.

**12-lead out-of-hospital ECG and advance ED notification**

Consensus on science. Two RCTs (LOE 2),326,327 six nonrandomised controlled trials (LOE 3),101,328—332 one retrospective cross-sectional study (LOE),106 and extrapolations from two feasibility studies (LOE 4;101; LOE 3)313 showed a reduction of 10—60min in the door-to-reperfusion interval for patients with STEMI when a 12-lead out-of-hospital ECG was obtained and interpreted by a physician, nurse, or paramedic and sent to the receiving hospital in advance (cellular ECG transmission or verbal communication).

One RCT (LOE 2)328 and five other studies (LOE 5102,324, LOE 4133; LOE 3135; LOE 5137) showed that 12-lead out-of-hospital ECGs with advance notification undertaken by out-of-hospital personnel does not increase on-scene time interval significantly (0.2—5.6 min) in patients with suspected AMI.

Four studies (LOE 3103,334,336; LOE 5335) showed that out-of-hospital personnel can acquire and transmit diagnostic-quality 12-lead out-of-hospital ECGs.

Treatment recommendation. Routine use of the 12-lead out-of-hospital ECG with advance ED notification may benefit STEMI patients by reducing the time interval to fibrinolysis.

Advance ED notification may be achieved with direct transmission of the ECG itself or verbal report (via telephone) of the ECG interpretation by out-of-hospital personnel.

**Interfacility transfer for primary PCI**

Consensus on science. Three RCTs (LOE 2)213,217,240 and one meta-analysis (LOE 1)219 documented safety and improved combined event rate (30-day combined rate of death, reinfarction, or stroke) when patients with STEMI from hospitals without the capability for primary PCI were transferred promptly for primary PCI at a skilled facility. A skilled facility provides access to PCI undertaken by a skilled operator in a high-volume center (i.e. >75 procedures per operator annually) with minimal delay214,223,228.

When combined in a meta-analysis (LOE 1),219 five RCTs (LOE 2)213,217,233,240,241 showed reduced mortality rates when patients with STEMI from hospitals without the capability for primary PCI were transferred promptly to a facility with such capability.

In one RCT (LOE 2)217 and one post hoc subgroup analysis of an RCT (LOE 7),246 it is unclear whether immediate out-of-hospital fibrinolysis, in-hospital fibrinolysis, or transfer for primary PCI is most efficacious for patients presenting with STEMI within 2—3h of the onset of symptoms.

Treatment recommendation. For patients with STEMI presenting >3h but <12h from the onset of symptoms, interfacility transfer from hospitals that lack primary PCI capability to centres capable of providing primary PCI is indicated if such a transfer...
can be accomplished as soon as possible. Optimally PCI should occur ≤90 min from first medical contact (i.e. contact with a healthcare provider who can make the decision to treat or transfer).

In patients with STEMI presenting ≤3 h from onset of symptoms, treatment is more time-sensitive, and there are inadequate data to indicate the superiority of out-of-hospital fibrinolysis, immediate hospital fibrinolysis, or transfer for primary PCI.

The time recommendations do not apply to patients in cardiogenic shock. In such patients the evidence supports early revascularisation therapy (primary PCI, early PCI, or surgery) compared with medical therapy.216

Out-of-hospital triage for PCI

Consensus on science. A single study (LOE 2)337 with insufficient power and some methodological concerns and a second post hoc subgroup analysis (LOE 7)246 failed to show that out-of-hospital triage for primary PCI was any better than out-of-hospital fibrinolysis in patients with STEMI in systems involving the presence of physicians in mobile intensive care units (MICUs).

No randomised studies directly compared out-of-hospital triage for primary PCI with fibrinolysis given at a community hospital. Extrapolations from four RCTs on interfacility transfer (LOE 7)213,217,240 suggest that out-of-hospital STEMI patients may do better with direct triage to a primary PCI facility because of the potential for earlier treatment. A cost-effectiveness substudy of the Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) trial337 using critical-care physicians during transport and for administration of fibrinolytics suggests that direct transport to a primary PCI facility may be more cost-effective than out-of-hospital fibrinolysis when transport can be completed in ≤60 min. But this study excluded patients considered to be at high risk for complications during transfer (e.g. cardiogenic shock).

Treatment recommendation. There is some limited evidence to recommend out-of-hospital triage for primary PCI for patients with uncomplicated STEMI who are ≤60 min away from a PCI site in systems that use MICUs with physicians on board with the proviso that the delay from decision to treat to balloon inflation is ≤90 min. Further studies are required to define appropriate triage and transport criteria.

Interfacility transfer for early PCI

Consensus on science. A strategy of fibrinolysis combined with transfer for early PCI (defined as PCI performed ≤24 h after fibrinolysis) is supported by six randomised trials (LOE 1223,338,339 and LOE 2241,340,341). The efficacy of this strategy is also supported by a post hoc nonrandomised comparison (LOE 3).146 But this strategy is not supported by other RCTs (LOE 1443–445; LOE 2223,240) and other nonrandomised studies or secondary analyses of the above trials (LOE 7).346 Several meta-analyses showed no benefit of early PCI (LOE 1).247–249 All but one of these trials were carried out in the 1990s before the era of coronary stenting. These studies did not use modern drugs or contemporary PCI techniques.

The feasibility of fibrinolysis combined with transfer for early PCI is supported by three lower level studies. One study is a small trial in which PCI was performed routinely (LOE 7),290 one is a randomised trial of low-dose fibrinolytics compared with placebo before immediate cardiac catheterisation and PCI as necessary (LOE 7),217 and one is a retrospective analysis (LOE 7).352

The efficacy of early PCI for patients with cardiogenic shock was shown in an RCT that showed improved mortality at six months and 1 year with early revascularisation (LOE 1),216 especially in patients <75 years. This was supported by a retrospective analysis (LOE 7).353

One RCT (LOE 2) showed improvement in secondary nonfatal outcomes when early PCI was used for patients who did not achieve reperfusion after fibrinolysis.354

All of the above studies involved in-hospital fibrinolysis. The use of prehospital fibrinolysis followed by early PCI has not been studied.

Treatment recommendation. There is inadequate evidence to recommend the routine transfer of patients for early PCI after successful fibrinolysis in community hospital EDs or out of hospital.

Transfer for early PCI is recommended as one strategy for early revascularisation for patients with cardiogenic shock, especially patients <75 years; or with haemodynamic instability or persistent symptoms of ischaemia after fibrinolysis.

Appendix A. Supplementary data

References


Part 5: Acute coronary syndromes


131. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina. Results of the TIMI-3 study of low-molecular-weight heparin in unstable angina. TIMI-3 Investigators. Circulation 1994;90:1593—601.


Part 5: Acute coronary syndromes

non-ST-segment-elevation acute coronary syndromes. [see Olmsted EA. Circulation 2001;104:2767–71.]


Part 5: Acute coronary syndromes


266 Part 5: Acute coronary syndromes


Part 5: Acute coronary syndromes


